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ABSTRACT
Human pluripotent stem cells (hPSCs) are an important
system to study early human development, model
human diseases, and develop cell replacement thera-
pies. However, genetic manipulation of hPSCs is chal-
lenging and a method to simultaneously activate
multiple genomic sites in a controllable manner is sorely
needed. Here, we constructed a CRISPR-ON system to
efﬁciently upregulate endogenous genes in hPSCs. A
doxycycline (Dox) inducible dCas9-VP64-p65-Rta
(dCas9-VPR) transcription activator and a reverse Tet
transactivator (rtTA) expression cassette were knocked
into the two alleles of the AAVS1 locus to generate an
iVPR hESC line. We showed that the dCas9-VPR level
could be precisely and reversibly controlled by the
addition and withdrawal of Dox. Upon transfection of
multiplexed gRNA plasmid targeting the NANOG pro-
moter and Dox induction, we were able to control
NANOG gene expression from its endogenous locus.
Interestingly, an elevated NANOG level promoted naïve
pluripotent gene expression, enhanced cell survival and
clonogenicity, and enabled hESCs to integrate with the
inner cell mass (ICM) of mouse blastocysts in vitro.
Thus, iVPR cells provide a convenient platform for gene
function studies as well as high-throughput screens in
hPSCs.
KEYWORDS CRISPR, transcription activation, human
pluripotent stem cells, NANOG, pluripotency
INTRODUCTION
Human pluripotent stem cells (hPSCs), including human
embryonic stem cells (hESCs) and human induced pluripo-
tent stem cells (hiPSCs), are capable of self-renewal indef-
initely and have the potential to differentiate into all cell types
in the human body. Therefore this system offers a useful
platform to study early human embryogenesis and a poten-
tial cell source for regenerative medicine. Moreover, func-
tional cells derived from hESCs can be used to model
human diseases in the context of drug toxicity tests and new
drug development. These applications rely on methods to
precisely control gene expression. However, because of
difﬁculties in culture and transfection, targeted regulation of
gene expression in hPSCs remains a technically challenging
task. A method for efﬁcient, rapid, and controllable gene
activation is sorely needed.
Recently, the clustered regularly interspaced short palin-
dromic repeat (CRISPR)/Cas9 system emerged as a pow-
erful and versatile tool for genome editing (Wiedenheft et al.,
2012). CRISPR was initially discovered as the adaptive
immune system of bacteria and archaea (Wiedenheft et al.,
2012). In response to viral and plasmid infection, bacteria
and archaea could cut and degrade the foreign DNA rec-
ognized by a matching spacer RNA with the help of the Cas9
enzyme (Wiedenheft et al., 2012). CRISPR was rapidly
transformed to a genome editing tool, and it has been shown
to work in a wide range of systems, from plants to human
cells, since the Cas9 nuclease can be directed easily to
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virtually anywhere in the genome using a short guide RNA
and cutting the target DNA (Hsu et al., 2014). In pluripotent
stem cells, the CRISPR system has been used to perform
highly efﬁcient gene knock-out and knock-in studies (Hsu
et al., 2014). In addition to genome editing, a nuclease
inactivated Cas9 (dCas9) was developed (Gilbert et al.,
2014). By fusing dCas9 with transcription activators and
repressors, such as VP64, and KRAB (Balboa et al., 2015;
Gilbert et al., 2014; Mandegar et al., 2016; Genga et al.,
2016), or with epigenetic modiﬁers, such as the catalytic
domain of acetyltransferase p300 (Hilton et al., 2015) and
Tet (ten eleven translocation) dioxygenase (Xu et al., 2016),
one can use the CRISPR system to activate or inhibit gene
expression or modify the histone and DNA methylation sta-
tus at the desired locus.
Because of its potential applications in regenerative
medicine, random insertion of foreign DNA into the genome
of hPSCs should be avoided, since this may cause harmful
mutations. The Adeno-Associated Virus Integration Site 1
(AAVS1) locus resides in the ﬁrst intron of the PPP1R12C
gene and has been used as a safe harbor for transgene
integration (Smith et al., 2008; Hockemeyer et al., 2009;
Lombardo et al., 2011; Qian et al., 2014; Zhu et al., 2014;
Genga et al., 2016). Here we generated an iVPR hESC line
by knocking-in the inducible dCas9-VPR system into the two
alleles of the AAVS1 locus. Detailed characterization of the
iVPR hESC demonstrated that dCas9-VPR protein could be
induced by Dox within 12 h and disappear after Dox with-
drawal. An inducible NANOG overexpression line (iNANOG)
was established based on the iVPR system. We found a
signiﬁcant increase in NANOG protein after Dox induction.
INANOG cells upregulated naïve pluripotency genes and
were able to grow for a signiﬁcant length of time in a naïve
state medium containing ERK and GSK3 inhibitors and
human LIF. The iVPR system can be a valuable system to
control gene expression from endogenous loci and serve as
platform for genome wide screens to identify new genes that
can regulate stem cell self-renewal and differentiation.
RESULTS
DCas9-VPR mediated robust ectopic and endogenous
gene activation in human cell lines
To construct a robust and tunable gene activation system in
hPSCs, we ﬁrst compared the activation efﬁciency of dCas9-
VPR (Chavez et al., 2015) with dCas9-VP64 (Kearns et al.,
2014) and the Doxycycline (Dox) inducible Tet-On transac-
tivator (rtTA) (Fig. 1A). We constructed plasmids to express
gRNA targeting the TetO sequence (gTetO), and tested the
ability of dCas9-VPR + gTetO or dCas9-VP64 + gTetO to
activate the synthetic TRE promoter driving enhanced blue
ﬂuorescent protein expression (TRE-BFP) in 293FT cells
(Fig. 1A). The Tet transactivator (rtTA) was used as positive
control (Fig. 1B). DCas9-VPR strongly activated BFP ﬂuo-
rescence, 43.1% of cells were BFP positive, while in the
rtTA + Dox and dCas9-VP64 groups, only 28.2% and 5.8%
of cells activated BFP, respectively (Fig. 1C and 1D).
Moreover, dCas9-VPR resulted in the strongest mean BFP
ﬂuorescence intensity, indicating that it is the strongest
activator among the three (Fig. 1D).
We next tested the dCas9-VPR function in hESCs.
DCas9-VPR, gTetO, and TRE-BFP plasmids were co-
transfected into H9 hESCs. In another group, rtTA and TRE-
BFP plasmids were co-transfected. FACS analysis showed
that nearly 17% of cells in the dCas9-VPR group turned on
BFP, while 24.7% of cells in the rtTA group were BFP posi-
tive after Dox induction, and only 0.6% of cells exhibited BFP
ﬂuorescence without Dox (Fig. 1E). Interestingly, the dCas9-
VPR group showed the strongest mean ﬂuorescence inten-
sity (Fig. 1F). This is consistent with our result based on
293FT cells and proves that dCas9-VPR is a robust tran-
scription activator, even compared with rtTA. We also tested
the activation effect of dCas9-VPR in mouse embryonic stem
cells (mESCs) and mouse embryonic ﬁbroblasts (MEFs) and
obtained similar results (Fig. S1A and S1B).
We then tested the efﬁciency of dCas9-VPR to activate
normally silenced pluripotency genes in human cells. Two
gRNAs targeting the -254 and -144 positions upstream of the
transcription start site (TSS) of the pluripotency gene
NANOG were selected (Fig. 2A). A GFP-2A-Puromycin
resistant gene expression cassette was placed after the
gRNA cassette both to monitor the transfection efﬁciency
and for selection (Fig. 2A). NANOG cannot be activated by
gNANOG alone or by dCas9-VPR together with the control
gTetO. However, introducing gNANOG and dCas9-VPR
together could elevate the NANOG transcript level by up to
150-fold in 293FT cells, indicating that it has a robust gene
activation function (Fig. 2C).
Next, we tested whether the dCas9-VPR system could
simultaneously activate multiple genes in human cells, we
designed 2 different gRNAs per gene promoter for HOXA10,
SNAIL1, MESP1, GATA5 and HOXA9. First we tested the
activation efﬁciency of these gRNAs towards their target
genes when transfected separately in 293FT cells (Fig. 2D).
Q-PCR analysis showed all of the ﬁve pairs of gRNAs can
activate their target gene upon co-transfection with dCas9-
VPR (Fig. 2D). We next pooled gRNA pairs of two genes
(2× gRNAs: MESP1, GATA5), three genes (3× gRNAs:
HOXA10, SNAIL1, HOXA9) or ﬁve genes (5× gRNAs:
HOXA10, SNAIL1, MESP1, GATA5 and HOXA9) to test the
co-activation efﬁciency. Upon co-transfection with dCas9-
VPR, different combination of gRNAs upregulated their tar-
get genes together (Fig. 2E), indicating that dCas9-VPR
system could be a useful tool for multiplexed endogenous
gene activation.
To validate the utility of the dCas9-VPR system in
hESCs, we transfected H9 hESCs with either dCas9-VPR
and gNANOG or with rtTA and NANOG coding DNA
sequence (CDS) joined to H2B-mCherry through a 2A pep-
tide driven by a TRE promoter. As shown in Fig. 3A, for the
dCas9-VPR group, increased NANOG protein expression (in
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Figure 1. The dCas9-VPR system leads to robust transcription activation in human cell lines. (A) Schematic diagram of the
gRNA guided dCas9-VPR gene activation system that consists of two parts: one plasmid contains dCas9-VPR driven by a CAG
promoter; another plasmid contains gRNA targeting the promoter of the gene of interest driven by the human U6 promoter, in this
case gTetO, and a PuroR selection cassette driven by an EF1α promoter. Upon co-transfection of the two plasmids, dCas9-VPR can
activate the BFP transcription downstream of the TRE promoter. (B) Tet-On system: rtTA protein can bind to the TRE promoter and
drive expression of the down-stream BFP gene in the presence of Dox. (C) 293FT cells were transfected with the reporter plasmid
containing BFP driven by the TRE promoter. They were either co-transfected with dCas9-VPR or dCas9-VP64 and gTetO plasmids,
or with the CAG-rtTA plasmid. Dox was added immediately after transfection. Cells were harvested 2 days after transfection and the
ﬂuorescence was analyzed using ﬂow cytometry. (D) Bar graph quantiﬁcation of mean ﬂuorescent intensity analyzed using the
FlowJo software v7.6.1. ***P < 0.001, ****P < 0.0001, n = 3. (E) H9 hESCs were electroporated with either rtTA or dCas9-VPR + gTetO
plasmids together with the TRE-BFP plasmid. Dox was added immediately after electroporation. Cells were harvested 3 days after
electroporation and analyzed using ﬂow cytometry. (F) Bar graph quantiﬁcation of the mean ﬂuorescent intensity analyzed using the
FlowJo software v7.6.1. N/A, not applicable. **P < 0.01, n = 2.
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red) can be detected in colonies with GFP ﬂuorescence.
Upon Dox induction, stronger NANOG was also visible in
Tet-On system transfected cells and co-localized with the
H2B-mCherry (Fig. 3A). Quantitative PCR (Q-PCR) and
Western blot conﬁrmed the elevated NANOG level induced
by either dCas9-VPR + gNANOG or NANOG CDS. The
transcript level of another pluripotency marker gene, OCT4,
was increased synergistically (Fig. 3B). Western blot analy-
sis conﬁrmed the upregulation of NANOG and OCT4 pro-
teins in transiently transfected H9 cells (Fig. 3C). We
generated a transgenic hESC line constitutively expressing
dCas9-VPR and observed no cytotoxicity, decrease in
pluripotency gene expression, or change in cell morphology
for long-term cultures (Fig. 3D and 3E). This suggests that
the dCas9-VPR system is suitable for gene activation stud-
ies in hPSCs.
Generation of an inducible idCas9-VPR hESC knock-in
line
To achieve efﬁcient, tunable, and reversible gene activation
while avoiding compromising the genome integrity of hPSCs,
we engineered an iVPR system by inserting the CAG
promoter driving the rtTA expression cassette and the TRE
promoter driving the dCas9-VPR cassette into the two alleles
of the AAVS1 locus on chromosome 19. H9 hESCs were co-
transfected with two donor plasmids containing dCas9-VPR
and M2rtTA, as well as a pair of Cas9 nickase plasmids with
AAVS1 targeting gRNAs to induce DNA double-strand break
(DSB) and homology recombination (HR) (Fig. S2A). After
puromycin and neomycin double selection for 2 weeks, we
picked and expanded 17 clones. Upon addition of Dox, all
the clones showed clear induction of dCas9-VPR protein
expression (Fig. S2B). Genomic DNA PCR was performed to
select correct targeted clones and rule out random insertions
(Fig. S2C). Clone 2, 6 and 8 had targeted insertion at both
AAVS1 alleles and without any random insertion (Fig. S2C).
They were chosen for further analysis. Southern blot con-
ﬁrmed that in all three clones, both alleles of AAVS1 con-
tained the correct insertion (Fig. 4A and 4B). Q-PCR analysis
showed that in hESCs, without Dox treatment, little dCas9-
VPR transcript could be detected, while after Dox addition,
strong dCas9-VPR expression was induced (Fig. 4C).
Karyotype analysis showed that all three clones had normal
46XX karyotype (Fig. S2D). IVPR clone 2 was chosen for
further study. Without Dox, we could not detect any dCas9-
VPR protein in iVPR cells. The dCas9-VPR protein
appeared after 12 h of Dox addition and reached a plateau at
24 h (Fig. 4D). While 6 h after Dox withdrawal, the dCas9-
VPR protein decreased, by 12 h, it decreased to a low level
and could not be detected anymore after 24 h (Fig. 4D). The
induction of dCas9-VPR from the AAVS1 locus was not
affected by differentiation. We induced mesoderm differen-
tiation by culturing cells in an RPMI medium supplemented
with albumin, ascorbic acid, transferrin, selenite, BMP4
(5 ng/mL) and CHIR99021 (2 μmol/L) as described by Bur-
ridge et al. (2015). Q-PCR analysis showed that after 3 days
of differentiation, pluripotency marker genes OCT4 and
SOX2 were signiﬁcantly downregulated, while dCas9-VPR
was highly expressed as long as Dox was present, regard-
less whether cells were in hESC culture medium E8 or in the
differentiation medium (Fig. 4E). Genes related to mesoderm
differentiation and epithelial to mesenchymal transition, such
as SNAIL, were strongly upregulated by BMP4 and
CHIR99021, conﬁrming that hESCs had taken a mesoderm
fate (Fig. 4E). These results suggest that the iVPR hESC line
can be used for efﬁcient and reversible gene activation.
Upregulation of NANOG by dCas9-VPR promoted naïve
state of pluripotency
The iVPR system provided a unique platform to investigate
gene functions through activation from the endogenous
locus. NANOG is a key regulator of pluripotency. We gen-
erated iNANOG hESCs by transfecting the PiggyBac based
gNANOG plasmid described earlier into iVPR clone 2, 6, and
8, followed by FACS selection of GFP+ cells. Q-PCR anal-
ysis showed that after 2 days of Dox treatment, only
b Figure 2. DCas9-VPR can be used to activate single or
multiple genes in 293FT cells. (A) NANOG gRNA targeting
sites were located at -254 bp and -144 bp upstream of the
NANOG transcription starting site (TSS); protospacer-adjacent
motif (PAM) sequences in red; black boxes indicate exons.
(B) DCas9-VPR and gNANOG plasmids were co-transfected
into 293FTcells. DCas9-VPR and gTetO plasmids were used as
control. Top panels, ﬂuorescence images of transfected cells;
gNANOG plasmid transfected cells showed strong GFP ﬂuo-
rescence. Bottom panel, ﬂow cytometry analysis of GFP+ cells
in each group. (C) Q-PCR analysis of NANOG expression 2
days after transfection; the dCas9-VPR system showed nearly
150-fold up-regulation of NANOG mRNA. Relative gene
expression values were normalized against GAPDH. Error bars
represent SEM. **P < 0.01, n = 3. (D) Activation of endogenous
genes by dCas9-VPR. DCas9-VPR was co-transfected with
gRNA pairs targeting HOXA10, SNAIL1, MESP1, GATA5 or
HOXA9, respectively. Cells were harvested 2 days after
transfection and subjected to Q-PCR analysis. All tested genes
showed signiﬁcant upregulation compared to the control group.
All expression levels were normalized against GAPDH. Error
bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, n = 3. (E) Simultaneously activation of multiple
endogenous genes in 293FT cells. DCas9-VPR was co-trans-
fected with 2× gRNAs (gMESP1, gGATA5), 3× gRNAs
(gHOXA10, gSNAIL1, gHOXA9) or 5× gRNAs (gHOXA10,
gSNAIL1, gMESP1, gGATA5 and gHOXA9). Cells were har-
vested 2 days after transfection. Q-PCR analysis conﬁrmed co-
upregulation of multiple genes targeted by pooled gRNAs. All
expression levels normalized against GAPDH. Error bars
represent SEM. *P < 0.05, **P < 0.01, ****P < 0.0001, n = 3.
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iNANOG cells showed a signiﬁcant increase (about 18 folds)
in the NANOG mRNA level, while iVPR cells, with or without
Dox, or iNANOG cells without Dox did not show any change
in NANOG expression, indicating that the iNANOG system is
tightly regulated (Fig. 5A). We also tested the time window of
NANOG down-regulation after Dox withdrawal. NANOG
mRNA was unchanged during the ﬁrst 12 h and decreased
after 24 h. It approached the background level after 48 h
(Fig. 5B). We next examined the change in NANOG protein
level after Dox addition and withdrawal. Western blot
revealed that dCas9-VPR protein became detectable 12 h
after Dox induction and reached a signiﬁcant level after 24 h
(Fig. 5C, dCas9, long exposure; LE). Accordingly, NANOG
protein showed an obvious increase after 24 h and main-
tained at high level as long as dCas9-VPR was present


























































































































































Figure 3. Activation of endogenous NANOG gene in hESCs by dCas9-VPR. (A) Immunostaining showing upregulation of
NANOG protein by the dCas9-VPR system. Cells were ﬁxed 5 days after transfection. WT Ctrl, untransfected H9 cells; Diff,
differentiated H9 cells induced by 10 μmol/L retinoic acid (RA); gNANOG, H9 cells co-transfected with dCas9-VPR and gNANOG
plasmids; NANOG CDS, cells co-transfected with CAG-rtTA and TRE driving NANOG-2A-H2B-mCherry. Dox were added
immediately after electroporation. All plasmids were based on the PiggyBac system and co-transfected with a plasmid containing
HyperPB transposase driven by a CAG promoter. Scale bar, 20 μm. (B) Q-PCR analysis of NANOG and OCT4 expression in H9 cells
5 days after transfection. All expression levels normalized against GAPDH. Error bars represent SEM. *P < 0.05, n = 3. (C) Western
blot analysis of NANOG and OCT4 protein expression in H9 hESCs. Cells were harvested 5 days after transfection without selection.
(D) DCas9-VPR constitutive expressing H9 cells showed similar clone morphology after long-term culture. Scale bar, 100 μm.
(E) Q-PCR result showing dCas9-VPR constitutive expressing H9 cells and wild-type H9 cells expressed similar amount of NANOG.
All expression levels normalized against GAPDH. Error bars represent SEM. ns. P > 0.05, ***P < 0.001, n = 3.
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removal, the dCas9-VPR protein decreased signiﬁcantly
(Fig. 5D, dCas9, short exposure; SE). The decline of the
dCas9-VPR protein was most apparent during the ﬁrst 24 h.
After 4 days without Dox, dCas9-VPR protein became
almost undetectable (Fig. 5D). Similarly, the NANOG protein
level dropped to the background level after 4 days of Dox
withdrawal (Fig. 5D). Q-PCR analysis showed that after Dox
induction, iNANOG signiﬁcantly upregulated naïve state
related genes such as OCT4, PRDM14, GDF3, and LEF-
TYB, while the early differentiation genes such as AFP was
signiﬁcantly downregulated (Fig. 5E). XIST, a long non-
coding RNA involved in X chromosome inactivation were
also downregulated after NANOG induction (Fig. 5F). The
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Figure 4. Generation of the iVPR hESC line. (A) Schematic view of wild type, targeted AAVS1 locus, and positions of Southern blot
probes. B (Bgl II site), S (Sph I site), EXT (external probe), INT (internal probe). The sizes of the expected bands are indicated at the
top. Blue lines indicate homology to the PPP1R12C intron. HA-L and HA-R, left and right homology arms. (B) Southern blot conﬁrmed
the correct targeted AAVS1 locus in the iVPR clone 2#, 6#, 8#. M, marker. (C) Q-PCR analysis of dCas9-VPR transcript levels with or
without Dox treatment. Expression levels were normalized against GAPDH. Error bar represents SEM. (D) Western blot of dCas9-
VPR protein level upon Dox addition and after Dox withdrawal in idCas9-VPR clone 2. The time points are indicated at the top.
(E) Q-PCR showing that the induction of dCas9-VPR was not affected by differentiation. Cells were induced to undergo mesoderm
differentiation for 3 days in the presence or absence of Dox. Gene expression levels were all normalized against GAPDH. Error bar
indicates SEM. ***P < 0.001, ****P < 0.0001, n = 3.
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surface marker, was increased and became more homoge-
neous afterNANOG elevation (Figs. 5GandS3). In addition to
elevated expression of pluripotency genes, iNANOG cells
also showed enhanced survival and proliferation abilities.
Clonogenicity assay showed that after Dox induction, twice as
many clones formed from dissociated iNANOG single cells
(Fig. 5H and 5I). Finally, we tested whether NANOG upregu-
lation by iVPRmay facilitate hESCs to enter the naïve state of
pluripotency. IVPR cells and iNANOG cells were cultured in
2iL medium which supplemented with ERK inhibitor
PD0325901, GSK3 inhibitor CHIR99021, human LIF, and
bFGF proteins with or without Dox addition (Silva et al., 2009;
Takashima et al., 2014). Upon changing to the 2iL medium,
hESCs colonies changed into a domed-shaped morphology
and became more compact (Fig. 5J and 5K). INANOG cells
without induction can only survive for no more than three
passages in the 2iL medium (Fig. 5J). Interestingly, Dox
induced iNANOG cells can grow in the 2iL medium for longer
than 9 passages with single cell dissociation and a 1:15 pas-
sage ratio (Fig. 5J and 5K). In contrast to iNANOG cells, Dox
treated iVPR cells could not survive in 2iL conditions (Fig. 5J).
Thus, upregulation of NANOG from its endogenous locus
signiﬁcantly improved single cell clonogenicity and permitted
hESCs to grow in a naïve state culture environment.
Upregulation of NANOG enabled hESCs to integrate
with mouse ICM in vitro
Entering the pluripotent ICM lineage is considered a more
stringent test for naïve state ESCs (Gafni et al., 2013;
Takashima et al., 2014). We next used in vitro human-mouse
blastocyst chimera assay to assess the functionality of
iNANOG cells (Fig. 6A). To exclude the inﬂuence of Dox
treatment only, wild type hESCs stably carrying gNANOG
(WTSG) were used as the control. For this series of exper-
iments, we also added Forskolin (a cAMP agonist) into the
2iL medium, since it had been shown to promote hPSCs to
enter the naïve state (Hanna et al., 2010; Ware et al., 2014;
Duggal et al., 2015). We refer to this medium as 2iL/FK.
iNANOG cells showed further enhanced proliferation in the
2iL/FK medium and were able to form large, dome-shaped
colonies (Fig. 6B), while cells without NANOG overexpres-
sion could only form small colonies (Fig. S4A). E3.5 blas-
tocysts were collected from ICR mice for hESC injection.
iNANOG cells and WTSG cells cultured with or without Dox,
in either the E8 or 2iL/FK medium, were dissociated into
single cells. 10–15 single cells were injected into the blas-
tocoel cavity and cultured in a 1:1 mixed KSOM:2iL/FK
medium for 24 h (Fig. 6A). Because cells without NANOG
overexpression only formed small colonies on feeder in the
2iL/FK medium, we could not obtain sufﬁcient pure hESCs
for blastocyst injection. Therefore, this group was omitted
from this series of experiments. Since all cells used for
injection contained GFP transgene expressed from the
gNANOG plasmid, the location of human cells in the mouse
blasocysts could be followed directly under the ﬂuorescence
microscope. 4–6 h after injection, most blastocysts con-
tained GFP positive human cells (Fig. 6B and 6C). After 24 h
of culture, many embryos still contained hESCs (Fig. 6B).
We used time-lapse imaging to monitor the activity of hESCs
in mouse blastocysts over time (Supplementary movie S1).
Interestingly, endogenous NANOG overexpression strongly
enhanced the survival of hESCs in mouse blastocysts. 12 h
after injection, 2iL/FK cultured Dox induced gNANOG cells
could be found in approximately 82% of blastocysts, while
E8 cultured Dox induced gNANOG cells were alive in 73% of
blastocysts (Figs. 6C and S4B). In contrast, without Dox
induction, E8 cultured iNANOG cells could only be seen in
49% of injected blastocysts (Figs. 6C and S4B). We next
b Figure 5. Upregulation of NANOG by dCas9-VPR promoted
clonogenicity and the naïve state of pluripotency.
(A) Q-PCR analysis of NANOG upregulation in iNANOG cells.
IVPR clones 2, 6, and 8 were electroporated with gRNA
expression plasmid targeting the NANOG promoter, as shown
in Fig. 2A. GFP positive cells were puriﬁed by FACS and
maintained as iNANOG cells. They were treated with or without
Dox (1 μg/mL) for 2 days. NANOG expression level was
normalized against GAPDH. Error bar represents SEM.
(B) Q-PCR analysis of NANOG down-regulation in iNANOG
cells. Dox was added for 2 days, then removed. Cells were
harvested at different time points, as indicated. NANOG
expression was normalized against GAPDH. Error bar repre-
sents SEM. (C) Western blot showing increased NANOG
protein expression in iNANOG cells at different time points
after Dox treatment. SE, short exposure; LE, long exposure; d,
day; h, h. (D) Western blot showing NANOG protein expression
decrease in iNANOG cells at different time points after Dox
withdrawal. SE, short exposure; LE, long exposure; d, day; h, h.
(E) Q-PCR analysis showing upregulation of pluripotency gene
OCT4, PRDM14, GDF3, and LEFTYB, and down-regulation of
differentiation gene AFP. Expression level all normalized
against GAPDH. Error bar represents SEM. N/A, not applicable.
ns. P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001,
n = 3. (F) Q-PCR analysis showing downregulation of XISTafter
NANOG induction. Expression level normalized against
GAPDH. Error bar represents SEM. ns. P > 0.05, *P < 0.05,
n = 3. (G) Flow cytometry analysis showing increased SSEA3
expression after NANOG induction. Data analyzed using the
FlowJo software v7.6.1. (H) Clonogenicity assay of iNANOG
cells. Alkaline phosphatase assay (dark blue) was used to
visualize undifferentiated colonies. (I) Bar graph quantiﬁcation
of the clonogenicity assay. ns. P > 0.05, *P < 0.05, n = 3.
(J) Morphology of iNANOG cells cultured in the 2iL medium.
NANOG overexpression (iNANOG + Dox) promoted long-term
cell growth in the 2iL medium. Representative images of
passages 1 and 8 (P1 and P8) are shown. Scale bar, 100 μm.
(K) Morphology of primed state iNANOG cells (without Dox) and
Dox induced iNANOG cells (passage 9, P9) in the 2iL medium.
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analyzed the locations of the transplanted hESCs. Injected
embryos were ﬁxed after 24 h of culture, stained with CDX2 (a
trophectoderm marker) and β-Catenin, and observed with a
confocalmicroscope.Different integration patternswereshown:
hPSCs integrated into the ICM region (ICM), inboth the ICMand
the trophectoderm (Multiple), only in the trophectoderm (TE),
and disappeared (None) (Fig. 6D). We also performed live
imaging to monitor the behavior of iNANOG cells in the mouse
blastocyst. Interetingly, 2iL/FK cultured iNANOG cells tend to
migrate with mouse inner cell mass cells as blastocyst hatching
from the zona pellucida (Fig. 6E). NANOG overexpression sig-
niﬁcantly improved the percentage of cells remaining in blasto-
cysts, and the 2iL/FK culture further increased the ICM
integration proportion (Figs. 6F, 6G, and S4C). On average, two
2iL/FK or E8 cultured iNANOG cells could be found in the ICM
region 24 h after injection, while without NANOG overexpres-
sion, hardly anyGFPcellswere seen in the ICM (Fig. 6G). Thus,
upregulation of NANOG from its endogenous locus greatly
enhanced cell survival and their subsequent ICM integration in
hPSC-mouse blastocyst chimeras.
DISCUSSION
In this study, we generated an inducible CRISPR-ON hESC
line by targeting the AAVS1 locus. Based on both our results
and those of Chavez et al. (2015), dCas9-VPR appeared to
be a stronger activator than VP64 to induce gene expression
from both ectopic and endogenous promoters. It even led to
a higher level of reporter gene activation compared with Tet-
ON rtTA, where VP64 was fused with Tet protein directly
bound to the TRE elements. This is likely due to the com-
bined effects of VP64, NF-κB transcactivating subunit p65,
and the viral transcription factor Rta, which together can
recruit a multitude of endogenous factors to achieve dra-
matically enhanced transcriptional activation. Other dCas9
based transcription activators have been generated. For
example, Balboa et al. found increased activation ability with
more VP16 fusing together. Using the longest version of
dCas9-VP192 combined with inducible systems, they
sucessfully facilitated human cell reprogramming and dif-
ferentiation (Balboa et al., 2015). Konermann et al. engi-
neered a structure-guided CRISPR synergistic activation
mediator system (SAM), where they engineered gRNA2.0 by
replacing the tetraloop and stem loop 2 of the original gRNA
with a minimal hairpin aptamer that speciﬁcally binds to MS2
bacteriophage coat proteins (Konermann et al., 2014). By
co-expression of dCas9-VP64, gRNA2.0, and MS2 fused
with p65 and the activation domain of the human heat-shock
factor 1 (HSF1), highly effective gene activation can be
achieved (Konermann et al., 2014). Tanenbaum et al. con-
structed a SunTag system: dCas9 was joined with 10 copies
of GCN4 peptide (SunTag), while VP64 was fused with scFv-
GCN4 (the single-chain variable fragment (scFv) antibody of
GCN4) (Tanenbaum et al., 2014). When co-expressed in the
cell, SunTag was bound by scFv-GCN4, and multiple copies
of VP64 resulted activation of the target gene (Tanenbaum
et al., 2014). Compared with the systems discussed above,
which required introducing tandem repeat large cassette or
the co-expression of two components in addition to the
gRNA, dCas9-VPR is a simple and effective option.
In our study, we chose to insert the iVPR system into the
AAVS1 locus, since it has been used as a ‘safe habor’ for
transgene insertion in human stem cell systems (Dekelver
et al., 2010). For example, Genga et al. constructed a GFP
labled H1 hESC line by knocking-in a CAG-GFP into the
AAVS1 locus. Besides, an inducible dCas9-KRAB gene
inhibition system was also introduced into the GFP-H1 cells.
By infecting sgRNA targeting the exdogenous CAG pro-
moter, they successfully realized CRISPR based inhibition of
exdogenous gene in hESCs (Genga et al., 2016). González
et al. inserted the Dox inducible Cas9 system into the 2
alleles of the AAVS1 locus of HUES8 hESCs (González
et al., 2014; Zhu et al., 2014; Zhu et al., 2015). The resulting
iCRISPR hESC line enabled selection-free gene knock-out
and the generation of lineage-speciﬁc knock-in reporters.
This demonstrated that when Cas9 was expressed in a
controllable manner from a suitable locus, the resulting cell
line can be a powerful platform for genome editing in nor-
mally hard to transfect human stem cells (Zhu et al., 2015).
Similarly, using the iVPR line, we found that the efﬁciency to
generate an iNANOG line was much improved. Upon Dox
addition and withdrawal, NANOG transcripts and proteins
b Figure 6. Upregulation of NANOG by idCas9-VPR pro-
moted hESC survival and ICM integration in mouse blas-
tocysts in vitro. (A) Cartoon showing in vitro hESC-mouse
blastocyst chimera formation assay. iNANOG cells were
cultured in E8 or 2il/FK medium with or without Dox, then
injected into E3.5 mouse blastocysts and cultured to E4.5 in
KSOM: 2il/FK = 1:1 medium in vitro. (B) Morphology of iNANOG
cells in culture and chimeric embryos. Top 2 rows, cells cultured
in E8 or 2iL/FK on feeders; scale bar, 100 μm. Bottom 2 rows,
E3.5 and E4.5 mouse blastocysts with iNANOG cells (GFP);
scale bar, 100 μm. (C) Survival curve of hESC in mouse
blastocysts over time. WTSG, wild type hESCs expressing
NANOG gRNA. The P value was calculated using the Log-rank
(Mantel-Cox) test. ns. P > 0.05, *P < 0.05, ***P < 0.001.
Detailed information is provided in Fig. S4B. (D) Confocal
images of E4.5 chimeric embryos. β-Catenin, yellow; CDX2,
red; DNA, blue; iNANOG cells, green. The ICM region is
highlighted by a dashed circle. Scale bar, 20 μm. (E) Selected
frame from time-lapse movie of iNANOG-mouse blastocyst
chimera. Arrows indicating iNANOG cells moved with mouse
inner cell mass cells during blastocyst hatching. Scale bar, 100
μm. (F) The proportion of blastocysts with hESC integration for
E4.5 embryos. Blastocysts with GFP cells in both ICM and TE
were counted as ICM. The percentage of embryos with ICM/TE/
None integration was labeled in the colored bar. (G) Dot graph
showing the number of iNANOG cells in the ICM region of E4.5
embryos. Cells, culture condition before injection, and number
of embryos were as listed. Error bars represent SEM. ns.
P > 0.05, **P < 0.01.
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could be up- and down-regulated in a highly repeat-
able manner, which greatly facilitated downstream experi-
ments. Recently, Ordovás et al. reported AAVS1-locus
mediated transgene inhibition in hESCs, and that inhibition
may due to different cassettes inserted into the locus (Or-
dovás et al., 2015). We tested the iVPR expression in both
undifferentiated hESCs and after induction of mesoderm
differentiation. The level of dCas9-VPR transcripts was even
higher upon Dox treatment after mesoderm induction
(Fig. 4E). The iVPR and iNANOG cells have been main-
tained for more than 6 months, and we did not observe any
reduction in the level of dCas9-VPR or NANOG induced by
Dox. Thus, results of us and other groups suggested that, in
most cases, AAVS1 locus integration is a reliable approach
to generate transgenic hPSCs.
NANOG is a master transcription factor for pluripotency in
both human and mouse ESCs (Mitsui et al., 2003; Boyer
et al., 2005; Chambers et al., 2007). During somatic cell
reprogramming to pluripotent stem cells, ectopic expression
of NANOG helped to speed up reprogramming and restrict
partially reprogrammed cells to the ground state (Hanna
et al., 2009; Silva et al., 2009). Different from mESCs, con-
ventional cultured hESCs are in a primed state, similar to the
epiblast stem cells in mice (Brons et al., 2007; Tesar et al.,
2007). Recently, multiple groups reported methods to obtain
naïve state hPSCs that resemble ground-state mESCs
(Gafni et al., 2013; Duggal et al., 2015; Takashima et al.,
2014; Theunissen et al., 2014). Takashima et al. showed that
ectopic expression of NANOG and KLF2 could reset the self-
renewal requirements of hPSCs so that they can be grown in
a medium containing ERK1/2 inhibitor PD0325901 and
GSK3 inhibitor CHIR99021, and adopt a domed-shaped
morphology similar to that of mESCs (Takashima et al.,
2014). Here we increased the expression of endogenous
NANOG by targeting a strong transcription activator, dCas9-
VPR, to its promoter. As expected, we observed upregula-
tion of naïve state genes such as GDF3, PRDM14, and
LEFTYB and downregulation of early differentiation gene
AFP. Interestingly, these iNANOG cells showed a signiﬁ-
cantly improved survival ability and clonogenicity when cul-
tured in the primed state, and they could grow in 2i plus LIF
conditions for more than nine passages. The improved sur-
vival and self-renewal of iNANOG cells was not due to the
effect of Dox treatment as described by Chang et al. (2014),
because Dox treated iNANOG cells showed signiﬁcantly
higher clonogenicity over Dox treated iVPR cells (Fig. 5H
and 5I). The enhanced survival ability seemed to have a
signiﬁcant inﬂuence on whether hPSCs can integrate with
the ICM of mouse blastocysts during in vitro culture. We
found that even when iNANOG cells were in the primed
state, after injection into mouse blastocysts, more cells
remained inside the blastocysts and some of the cells were
able to integrate with mouse ICM cells (Fig. 6F and 6G).
Culturing iNANOG cells in 2iL/FK naïve state medium
(Duggal et al., 2015) further improved the ICM integration
rate (Fig. 6F and 6G). INANOG cells displayed highly
dynamic interactions with mouse ICM cells, as observed in
time-lapse movies (Supplementary movie S1). They migra-
ted with mouse ICM cells as blastocysts hatched from zona
pellucida. However, despite enhanced survival ability of
iNANOG cells, many injected cells died over time. After 24 h,
more than 30% of injected blastocysts lost all iNANOG cells
and more than 60% of blastocysts lost the injected hESCs if
NANOG was not overexpressed (Fig. 6F). This was partially
caused by poor survival of hESCs in the IVC-1 and -2 media
designed to culture peri-implantation mouse and human
embryos (Bedzhov and Zernicka-Goetz, 2014; Deglincerti
et al., 2016; Shahbazi et al., 2016) (Fig. S4D). Thus, to
achieve better naïve hPSC and mouse ICM integration, a
culture medium suitable for both mouse blastocysts and
hPSCs may be needed. The effect of NANOG overexpres-
sion on cell survival and self-renewal is also in accordance
with the observation that chromosome 12, where the
NANOG gene is located, is the most frequently gained
chromosome in culture adapted hPSCs (Baker et al., 2007)
and during hiPSC generation (Taapken et al., 2011). More-
over, NANOG was reported to be upregulated by a number
of factors such as STAT3, Hedgehog signaling, hypoxia, etc.,
in human cancers, and repression or ablation of NANOG
inhibited tumor initiation (Gong et al., 2015). Thus, iNANOG
hESCs, where the endogenous NANOG can be activated by
dCas9-VPR in a controllable manner, may also be a good
system to study the process of hPSC adaptation and
cancerous transformation.
In summary, the iVPR hESC line generated and charac-
terized in this study offered a convenient, stable, and highly
controllable platform for gene activation studies. It can also
be used to investigate the function of regulatory elements in
the genome such as super enhancers as well as for genome
wide screens using established human gRNA libraries.
MATERIALS AND METHODS
HESC culture
H9 hESCs (WiCell Institute) were maintained on inactivated mouse
embryonic ﬁbroblast (MEF) cells in standard hESC medium con-
sisting of KO-DMEM (Invitrogen) supplemented with 1× Nonessen-
tial Amino Acids (NEAA) (Invitrogen), 0.1 mmol/L 2-mercaptoethanol
(Sigma-Aldrich), 1 mmol/L GlutaMAX (Invitrogen), 20% Knock-out
serum-replacement (KOSR) (Invitrogen) and 4 ng/mL bFGF (Pe-
protech). Cells were cultured at 37°C in a humidiﬁed atmosphere
with 5% CO2 in air. They were passaged with 1 mg/mL collagenase
IV (Invitrogen) and seeded onto MEFs. For feeder-free culture,
hESCs were grown for more than three passages on Matrigel
(growth factor reduced, BD Biosciences) in the absence of feeders in
E8 medium (Invitrogen).
Plasmid construction
DCas9-VPR was constructed by fusing the nuclease deﬁcient Cas9
(dCas9) with transcription activator VP64, p65, and Rta in tandem as
described by Chavez et al. (Maeder et al., 2013). For constitutive
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expression, dCas9-VPR was placed behind a CAG promoter in a
PiggyBac vector also containing a PGK promoter driving a hygro-
mycin resistance gene. For inducible expression from the AAVS1
locus, dCas9-VPR was placed behind a TRE promoter in the AAVS1
homologous recombineering donor plasmid, as shown in Fig. S2A.
DCas9-VP64 was constructed by fusing dCas9 with VP64. Tet-On
system was obtained from Clontech (http://www.clontech.com).
PiggyBac plasmids were generous gift from the Sanger institute,
Cambridge, UK (http://www.sanger.ac.uk). The multiple NANOG
gRNA expression plasmid was constructed by SynGene (http://
syngen.tech) as depicted in Fig. 2A.
Naïve state culture condition for hPSCs
For naïve state conversion, cells cultured in standard hESC medium
on MEFs were dissociated to single cells using 0.05% trypsin/EDTA
solution (Invitrogen), replated on MEFs, and cultured overnight in
standard hESC medium supplement with 10 μmol/L Rho Kinase
(ROCK)-inhibitor Y-27632 (Calbiochem). The next day, the standard
medium was changed to the 2iL or 2iL/FK (for injection) medium,
which consisted of KO-DMEM (Invitrogen), 20% KOSR, 1×NEAA,
0.1 mmol/L 2-mercaptoethanol, 1 mmol/L GlutaMAX, 12 ng/mL
bFGF, 10 ng/mL human recombinant LIF (Peprotech), 1 μmol/L
ERK1/2 inhibitor PD0325901 (Peprotech), 3 μmol/L GSK3 inhibitor
CHIR99021 (Peprotech), 10 μmol/L Forskolin (Peprotech), and
50 μg/mL ascorbic acid (Sigma). HESCs changed to a dome-shaped
morphology within 4–6 days after culturing in the 2iL or 2iL/FK
medium and were passaged every 4 days as single cells using
0.05% trypsin/EDTA.
Cardiac mesoderm differentiation from hESCs
For cardiac mesoderm differentiation, hESCs maintained on Matrigel
(growth factor reduced, BD Biosciences) in E8 were dissociated into
single cells with Accutase (Invitrogen), then seeded onto Matrigel-
coated tissue culture dishes at a density of 5 × 104 cells/cm2 and
cultured in E8 for 3 days. Then the medium was switched to the
RPMI1640 medium supplemented with Albumin, Ascorbic acid,
transferrin, selenite, 5 ng/mL BMP4 (R&D Systems), and
CHIR99021 to induce cardiac mesoderm formation.
Quantitative PCR
Total RNA was extracted with TRIZOL (Invitrogen). 1 μg RNA of
each sample was used for reverse transcription with Superscript III
(Invitrogen). Q-PCR reactions were performed using GoTaq qPCR
Master Mix (Promega) in a CFX96 Real-Time System (Bio-Rad).
The relative expression level of each gene was normalized against
the Ct (Critical Threshold) value of the house-keeping gene GAPDH
using the Bio-Rad CFX Manager program. Primer sequences are
listed in table S2.
Antibodies, immunostaining, Western blot, and FACS analysis
For immunostaining, cells were ﬁxed in 4% paraformaldehyde (PFA)
in PBS, permeabilized in 0.5% Triton X-100 (Sigma), blocked in 5%
normal goat serum (Origene) and incubated with primary antibodies
against NANOG (1:200), SSEA3 (1:200) in 4°C overnight and
detected by DyLight 488- or 549-conjugated secondary antibodies
(Thermo). Nuclei were stained with DAPI (Sigma). A Nikon Ti-U
ﬂuorescence microscope was used for image acquisition. For
western blot, cells were lysed in a RIPA buffer (Applygen, http://
applygen.com.cn) with Protease Inhibitor Cocktail (Roche). Total
proteins were separated on a 12% SDS/PAGE gel, transferred to
nitrocellulose membrane (Whatman). The membrane was blocked
with 5% non-fat dry milk in TBST and then incubated with primary
antibodies against Cas9 (Genetex, 1:1000), GAPDH (CWBio,
1:1000), OCT4 (Santa Cruz, 1:1000) and NANOG (Cell Signaling
Technology, 1:1000). After washing, the membrane was incubated
with anti-mouse or anti-rabbit peroxidase-conjugated secondary
antibodies (ZSGB-Bio http://www.zsbio.com/). Bands recognized by
antibodies were revealed by ECL reagent (Pierce). For FACS
analysis, cells were ﬁrst dissociated with 0.05% Trypsin in 0.2%
EDTA and PBS. FACS was performed on a Fortessa ﬂow cytometer
(Becton Dickinson).
Mouse blastocyst injection and in vitro culture
The animal facility of Tsinghua University has been accredited by the
AAALAC (Association for Assessment and Accreditation of Labo-
ratory Animal Care International) and all animal protocols used in
this study were approved by the IACUC (Institutional Animal Care
and Use Committee) of Laboratory Animal Research Center of
Tsinghua University. Mouse morula were collected from ICR females
2.5 days post-coitus and cultured in KSOM medium (95 mmol/L
NaCl, 2.5 mmol/L KCl, 0.35 mmol/L KH2PO4, 0.2 mmol/L
MgSO4·7H2O, 0.2 mmol/L glucose, 10 mmol/L sodium lactate, 25
mmol/L NaHCO3, 0.2 mmol/L sodium pyruvate, 1.71 mmol/L
CaCl·2H2O, 0.01 mmol/L EDTA, 1 mmol/L L-glutamine, 0.1 mmol/L
EAA, 0.1 mmol/L NEAA, 4 mg/mL BSA) at 37°C, 5% CO2 for 24 h to
get blastocysts (Hogan et al., 1986). HESCs were brieﬂy treated
with Accutase for single cell and injected (∼10–15 cells for each
embryo) on a Nikon microscope ﬁtted with piezo-driven Eppendorf
NK2 micromanipulator, CellTram air and CellTram Vario. After
injection, embryos containing hESCs were cultured in medium
supplemented with naïve culture medium:KOSM (1:1) (Chen et al.,
2015) in 37°C, 5% CO2 incubator. After injected embryos reformed
blastocoel, the chimera embryos were live cell imaged using Leica
microscope ﬁtted with a live cell imaging system and ﬁxed after 24–
36 h post-injection for staining and confocal imaging. For embryo
immunostaining, zona pellucida-free injected embryos were ﬁxed
with 3.5% paraformaldehyde, permeabilized in 0.5% Triton X-100
(Sigma) and blocked with 5% BSA and then incubated with primary
antibodies against CDX2 (BioGenex), β-Catenin (1:50, Abcam) and
detected by DyLight 549- or 633- conjugated secondary antibodies
(Thermo). Nuclei were stained with DAPI (Sigma). A Nikon-A1 ﬂu-
orescence microscope was used for image acquisition.
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM).
Statistical signiﬁcance was determined by Student’s t-test (two-tail)
for two groups or one-way Analysis of Variance (ANOVA) for multiple
groups using Graphpad software. P < 0.05 was considered
signiﬁcant.
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